Back to Search
Start Over
Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria.
- Source :
-
Helicobacter [Helicobacter] 2018 Aug; Vol. 23 (4), pp. e12498. Date of Electronic Publication: 2018 Jun 13. - Publication Year :
- 2018
-
Abstract
- Background: Bismuth quadruple therapy is the treatment of choice for the first-line therapy of Helicobacter pylori infection in areas of high clarithromycin resistance. Currently, the impact of the promising treatment on gut microbiota remains unclear.<br />Aim: To investigate the short-term and long-term impacts of bismuth quadruple therapy on gut microbiota.<br />Methods: Adult patients with H. pylori-related gastritis were treated with 14-day bismuth quadruple therapy. Fecal samples were collected before treatment at week 2, week 8, and week 48. Nucleic acid extraction from fecal samples was performed. The V3-V4 region of the bacterial 16S rRNA gene was amplified by polymerase chain reaction and sequenced with the MiSeq followed by data analysis using Qiime pipeline.<br />Results: Eleven patients received complete follow-up. Before treatment, the most abundant phyla were Firmicutes (45.3%), Bacteroidetes (24.3%), Proteobacteria (9.9%), and Actinobacteria (5.0%). At the end of bismuth therapy, the relative abundances of Bacteroidetes and Actinobacteria decreased to 0.5% (P < .001) and 1.3% (P = .038), respectively. Additionally, the relative abundance of Verrucomicrobia also decreased from 3.2% to 1.11E-3% (P = .034). In contrast, the relative abundances of Proteobacteria and Cyanobacteria increased (P < .001 and P = .003, respectively). At week 8, the relative abundances of all phyla restored to the levels at baseline. The relative abundances of all phyla at week 48 also did not significantly differ from those at baseline. During eradication therapy, 6 patients (55%) reported at least 1 adverse event. The relative abundance of phylum Proteobacteria in patients with adverse effects was more than that in patients without adverse effects (68.7% ± 8.8% vs 43.4% ± 25.5%; P = .048).<br />Conclusions: Bismuth quadruple therapy for H. pylori eradication can lead to short-term dysbiosis of gut microbiota. The increase in Proteobacteria in gut microbiota may attribute to the development of adverse effects during bismuth quadruple therapy.<br /> (© 2018 John Wiley & Sons Ltd.)
- Subjects :
- 2-Pyridinylmethylsulfinylbenzimidazoles adverse effects
2-Pyridinylmethylsulfinylbenzimidazoles therapeutic use
Actinobacteria genetics
Actinobacteria isolation & purification
Adult
Anti-Bacterial Agents therapeutic use
Bacteroidetes genetics
Bacteroidetes isolation & purification
Bismuth therapeutic use
Drug Therapy, Combination adverse effects
Dysbiosis microbiology
Feces microbiology
Female
Helicobacter Infections microbiology
Helicobacter pylori drug effects
Helicobacter pylori physiology
Humans
Male
Metronidazole adverse effects
Metronidazole therapeutic use
Middle Aged
Pantoprazole
Proteobacteria genetics
Proteobacteria isolation & purification
Proton Pump Inhibitors adverse effects
Proton Pump Inhibitors therapeutic use
Tetracycline adverse effects
Tetracycline therapeutic use
Young Adult
Actinobacteria growth & development
Anti-Bacterial Agents adverse effects
Bacteroidetes growth & development
Bismuth adverse effects
Dysbiosis etiology
Gastrointestinal Microbiome drug effects
Helicobacter Infections drug therapy
Proteobacteria growth & development
Subjects
Details
- Language :
- English
- ISSN :
- 1523-5378
- Volume :
- 23
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Helicobacter
- Publication Type :
- Academic Journal
- Accession number :
- 29897654
- Full Text :
- https://doi.org/10.1111/hel.12498